echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Universal CAR-NK for relapsed/refractory B-cell lymphoma, 3/6 cases achieved CR

    Universal CAR-NK for relapsed/refractory B-cell lymphoma, 3/6 cases achieved CR

    • Last Update: 2022-05-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 25, U.
    S.
    time, Nkarta Therapeutic (later known as Nkarta) announced the latest clinical data on the company’s two CAR-NK pipelines, NKX101 (targeting NKG2D) and NKX019 (targeting CD19), in the treatment of hematological tumors

    .

    On April 25, U.
    S.
    time, Nkarta Therapeutic (later known as Nkarta) announced the latest clinical data on the company’s two CAR-NK pipelines, NKX101 (targeting NKG2D) and NKX019 (targeting CD19), in the treatment of hematological tumors

    .

    NKX019 is a CD19-targeting CAR-NK cell therapy from Nkarta and a "universal" CAR-NK cell therapy
    .
    Since CD19 is overexpressed in a variety of hematological tumors, NKX019 can be used to treat a variety of hematological malignancies

    .

    NKX019 is a CD19-targeting CAR-NK cell therapy from Nkarta and a "universal" CAR-NK cell therapy
    .
    Since CD19 is overexpressed in a variety of hematological tumors, NKX019 can be used to treat a variety of hematological malignancies

    .

    In a clinical trial evaluating NKX019 for the treatment of relapsed/refractory B-cell lymphoma , subjects (N=13) included patients with multiple types of lymphoma, 5 with large B-cell lymphoma (LBCL), 3 with follicular Lymphoma (FL), 1 marginal zone lymphoma (MZL), 3 mantle cell lymphoma (MCL), 3 B-cell acute lymphoblastic leukemia (B-ALL) at high dose (10x10 8 CAR-NK cells , 3 infusions) group, of 6 evaluable patients: 5 achieved objective responses (ORR=83%) and 3 achieved complete responses (CR=50%), including one with diffuse large B-cell lymphoma patient and one mantle cell tumor patient
    .

    .

    Lymphoma leukemia high-dose (10x10 8 CAR-NK cells, 3 infusions) group, of 6 evaluable patients: 5 achieved objective response (ORR=83%), 3 achieved complete response (CR=50%) , including one patient with diffuse large B-cell lymphoma and one patient with mantle cell tumor
    .

    .
    8

    Likewise, no dose-limiting toxicities, as well as adverse events similar to the side effects of CAR-T
    therapy, were found in this trial .

    CAR-T

    leaves a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.